SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Susan B. Anthony — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSusan B. Anthony
Date of birth1820-02-15
IdentifiersMRN HR-NI014-SYN-TD; SSN (made up) 000-14-7302
Document date1905-06-29
AuthorHarold Pemberton, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month heart failure and blood pressure review. [S]

History of Present Illness

Miss Anthony returns for her three-month review. She has had no swelling for six weeks and climbs stairs without stopping. Her morning weight has held at 56.0 to 56.4 kg for a month. She has resumed a reduced lecture schedule and walks a mile a day. She has had no dizziness on spironolactone, no breast tenderness, and no muscle cramps. She asks whether she still needs the daily water pill, because it limits her travel. [S]

ElementDetail
Interval changeNo edema for six weeks; stairs without stopping
Weight diaryStable at 56.0 to 56.4 kg for a month
Medication toleranceNo dizziness, breast tenderness, or cramps on spironolactone
FunctionWalking a mile a day; reduced lecture schedule
Patient goalFewer diuretic days so she can travel
NYHA classI to II

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improved; no weight gain
CardiovascularNegativeNo chest pain, palpitations, orthopnea, or edema
RespiratoryNegativeBreathless only on long climbs
GenitourinaryPositiveUrgency on diuretic mornings; no dysuria
NeurologicalNegativeNo dizziness on standing
PsychiatricNegativeMood good; PHQ-2 score 0

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Furosemide 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1905-03-16 to 1905-06-29completedS
Furosemide 20 mg oral tablet, one tablet by mouth as needed for a weight gain of more than 1 kg in a day or 2 kg in a weekOne tablet by mouth once daily as needed for weight gainOral route1905-06-29activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1905-03-16activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth dailyOne-half tablet by mouth dailyOral route1905-03-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1905-06-29Body height165cmS
1905-06-29Body weight56.2kgS
1905-06-29Body mass index (BMI) [Ratio]20.6kg/m2S
1905-06-29Systolic blood pressure132mm[Hg]S
1905-06-29Diastolic blood pressure74mm[Hg]S
1905-06-29Heart rate72/minS
1905-06-29Respiratory rate16/minS
1905-06-29Body temperature36.7CelS
1905-06-29Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1905-06-29Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma720pg/mL<=125 pg/mLHighS
1905-06-29Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1905-06-29Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1905-06-29Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.59-1.04 mg/dLNormalS
1905-06-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1900)/1.73 sq M61mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1905-06-29Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
1905-06-29Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
1905-06-29Overall summary score [KCCQ-12]70{score}S
1905-06-29Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 1905-06-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell, energetic
NeckJugular venous pressure 6 cm
LungsClear
HeartRegular rhythm; soft S4
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Heart failure with preserved ejection fraction, NYHA class II to III at diagnosis; synthetic modern diagnosis linked to the documented 1785 heart failureactiveconfirmed I50.32S — Synthetic diagnosis confirmed by echocardiogram in the modern episode; the 1906 cause of death remains D.
Hypertensive heart disease with heart failureactiveconfirmed I11.0S — Synthetic diagnosis; no blood pressure from her lifetime is recorded in the cited sources.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBasic metabolic panel with magnesium1 to 2 weeks after starting or changing therapy; every 3 to 6 months when stableCompleted todayPotassium 4.5, eGFR 61. This is the first panel since spironolactone started three months ago
LaboratoryBasic metabolic panel 1 to 2 weeks after starting spironolactoneOnce, after starting a mineralocorticoid antagonistDeferredNot drawn in the two-week window, a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted; the reminder is now in her chart
LaboratoryNT-proBNPSelectively in outpatient follow-upCompleted today720 pg/mL, down from 1650; informs decongestion, not used to titrate therapy
ExaminationBlood pressure, heart rate, weight, jugular venous pressure, edema, lungsEvery visitCompleted todayEuvolemic at 56.2 kg
SurveyNYHA functional classEvery visitCompleted todayClass I to II
SurveyKCCQ-12Every 3 to 6 monthsCompleted today70, up 18 points from baseline
SurveyDepression screen (PHQ-2)PeriodicallyCompleted todayScore 0
ImagingEchocardiogramOnly with unexplained clinical changeNot indicatedImproving as expected; routine repeat imaging is not recommended
ReferralCardiac rehabilitationIf exercise tolerance plateausNot indicatedExercise tolerance still improving with daily walking
Self-managementDaily weight diary and travel planEvery visitCompleted todayTravel weight plan written today

Goal progress:

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026)

Follow-up: Six-month heart failure review with a basic metabolic panel and KCCQ-12. Next scheduled visit 1905-09-28: six-month heart failure review. [S]